Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC01170 (Long intergenic non-protein coding RNA 1170) is an intergenic long non-coding RNA located on chromosome 5q23.2. It is classified as a lincRNA, defined by its length (>200 nt) and its lack of overlap with protein-coding genes. LINC01170 is overexpressed in endometrial carcinoma and functions as an oncogene by promoting cell proliferation, cell cycle progression, and inhibiting apoptosis via the PI3K/AKT signaling pathway. Knockdown experiments indicate that reduction of LINC01170 leads to decreased proliferation, increased cell cycle arrest, and apoptosis in endometrial cancer cells. Its expression level correlates with disease stage and prognosis, making it a putative therapeutic and diagnostic target in oncology.
When upregulated: *Promotes cancer progression* by activating AKT signaling, leading to increased cell survival and proliferation. When inhibited or knocked down: Decreases AKT activity, arrests cell cycle, increases apoptosis in endometrial cancer cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1170 (LINC01170).